Join Growin Stock Community!

Inventiva s.a.IVA.US Overview

US StockHealthcare
(No presentation for IVA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

IVA AI Insights

IVA Overall Performance

IVA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

IVA Recent Performance

-4.01%

Inventiva s.a.

0.05%

Avg of Sector

-0.31%

S&P500

IVA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

IVA Key Information

IVA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

IVA Profile

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

Price of IVA

IVA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

IVA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
79.45
PB Ratio
2.10
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
108.14%
Net Margin
-2091.32%
Revenue Growth (YoY)
-32.93%
Profit Growth (YoY)
-23.15%
3-Year Revenue Growth
358.64%
3-Year Profit Growth
160.44%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-5.20
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
79.45
PB Ratio
2.10
Price-to-FCF
-
Gross Margin
108.14%
Net Margin
-2091.32%
Revenue Growth (YoY)
-32.93%
Profit Growth (YoY)
-23.15%
3-Year Revenue Growth
358.64%
3-Year Profit Growth
160.44%

  • When is IVA's latest earnings report released?

    The most recent financial report for Inventiva s.a. (IVA) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IVA's short-term business performance and financial health. For the latest updates on IVA's earnings releases, visit this page regularly.

  • How much debt does IVA have?

    As of the end of the reporting period, Inventiva s.a. (IVA) had total debt of 132.8M, with a debt ratio of 0.74. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does IVA have?

    At the end of the period, Inventiva s.a. (IVA) held Total Cash and Cash Equivalents of 122.08M, accounting for 0.68 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.